Postscript on Sci-Hub: The University Press Edition

Not only is Sci-Hub pirating STM articles; it also has built a large collection of unauthorized university press monographs. This undermines the argument that Sci-Hub is an activist site fighting against corporate greed, as the university press community typically operates at a deficit. But university presses have many other challenges, and the threat posed by Sci-Hub is not the largest among them.

Integrate to Innovate: Using Standards to Push Content Forward

While many of the traditional publishing tasks remain intact, new tasks that are much more technical in nature have changed the skill sets required to be scholarly publishers. As new and developing standards and services such as Funder Identification, ORCID, CHORUS, and more come online, publishers and their vendors must integrate when they would rather innovate. The trick is in realizing where integration allows more innovation.

A Multiplicity of University Publishing

There continue to be calls to consolidate all publishing activity in a single organization or unit. The various participants in scholarly communications often are hostile to the very idea of competition. But the evidence is otherwise: a diversity of publishing venues, all operated independently, yield better and more innovative results.

Complexity and Misrepresentation in the New York Times

Robert Harington comments on a New York Times article by Kate Murphy , published on Sunday 13th March, 2016, suggesting that when journalists write such an article they, do not fan the flames of fundamentalism, recognize the complexity at hand, and understand that there is a constructive debate to be had.

Why Is ClinicalTrials.gov Still Struggling?

With no clear benefits to researchers, a frustrating user experience, and no penalties for non-compliance, ClinicalTrials.gov is becoming increasingly irrelevant to clinical researchers and the world at large with each passing day. What does this mean for public access to research results? Is an obligation to patients putting themselves at risk in trials being breached? Why has it failed to live up to its potential?